Pharmacokinetic/pharmacodynamic assessment of a novel, pharmaceutical lipid–aspirin complex: results of a randomized, crossover, bioequivalence study

Dominick J. Angiolillo, Deepak L. Bhatt, Frank Lanza, Byron Cryer, Jin fei Dong, Walter Jeske, Ronald R. Zimmerman, Estela von Chong, Jayne Prats, Efthymios N. Deliargyris, Upendra Marathi

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Aspirin (acetylsalicylic acid, ASA) can lead to gastrointestinal mucosal injury through disruption of its protective phospholipid bilayer. A liquid formulation of a novel pharmaceutical lipid–aspirin complex (PL-ASA) was designed to prevent this disruption. We sought to determine the pharmacokinetic (PK)/pharmacodynamic (PD) characteristics of PL-ASA compared with immediate release aspirin (IR-ASA). In this active-control crossover study, 32 healthy volunteers were randomized to receive 1 of 2 dose levels (a single dose of 325 mg or 650 mg) of either PL-ASA or IR-ASA. After a 2-week washout period between treatment assignments, subjects received a single dose of the alternative treatment, at the same dose level. The primary objectives of the study were to assess, for PL-ASA and IR-ASA at 325 mg and 650 mg dose levels, PK and PD bioequivalence, and safety, over a 24–h period after administration of both drugs. PK parameters were similar for PL-ASA and IR-ASA, and met FDA-criteria for bioequivalence. Regarding PD, both drugs also showed Cmin TxB2 values below 3.1 ng/mL (cut-off associated with decreased cardiovascular events) and > 99% inhibition of serum TxB2 (≥ 95% inhibition represents the cut-off for aspirin responders) along with similar results in several secondary PK/PD parameters. There were no serious adverse events or changes from baseline in vital signs or laboratory values in either of the 2 treatment groups. PL-ASA’s novel liquid formulation has similar PK and PD performance compared with IR-ASA, supporting functional and clinical equivalence. These data coupled with the improved gastric safety of PL-ASA suggest that this novel formulation may exhibit an improved benefit-risk profile, warranting evaluation in future trials. Clinical trial registration:http://www.clinicaltrials.gov. Unique Identifier: NCT04008979.

Original languageEnglish (US)
JournalJournal of Thrombosis and Thrombolysis
DOIs
StateAccepted/In press - Jan 1 2019
Externally publishedYes

Fingerprint

Therapeutic Equivalency
Cross-Over Studies
Aspirin
Pharmacokinetics
Pharmaceutical Preparations
Safety
Vital Signs

Keywords

  • Aspirin
  • Bioequivalence
  • Pharmacodynamic
  • Pharmacokinetic
  • Platelet

ASJC Scopus subject areas

  • Hematology
  • Cardiology and Cardiovascular Medicine

Cite this

Pharmacokinetic/pharmacodynamic assessment of a novel, pharmaceutical lipid–aspirin complex : results of a randomized, crossover, bioequivalence study. / Angiolillo, Dominick J.; Bhatt, Deepak L.; Lanza, Frank; Cryer, Byron; Dong, Jin fei; Jeske, Walter; Zimmerman, Ronald R.; von Chong, Estela; Prats, Jayne; Deliargyris, Efthymios N.; Marathi, Upendra.

In: Journal of Thrombosis and Thrombolysis, 01.01.2019.

Research output: Contribution to journalArticle

Angiolillo, Dominick J. ; Bhatt, Deepak L. ; Lanza, Frank ; Cryer, Byron ; Dong, Jin fei ; Jeske, Walter ; Zimmerman, Ronald R. ; von Chong, Estela ; Prats, Jayne ; Deliargyris, Efthymios N. ; Marathi, Upendra. / Pharmacokinetic/pharmacodynamic assessment of a novel, pharmaceutical lipid–aspirin complex : results of a randomized, crossover, bioequivalence study. In: Journal of Thrombosis and Thrombolysis. 2019.
@article{dedc21be8deb4567b8ad0b70c1e0e9d8,
title = "Pharmacokinetic/pharmacodynamic assessment of a novel, pharmaceutical lipid–aspirin complex: results of a randomized, crossover, bioequivalence study",
abstract = "Aspirin (acetylsalicylic acid, ASA) can lead to gastrointestinal mucosal injury through disruption of its protective phospholipid bilayer. A liquid formulation of a novel pharmaceutical lipid–aspirin complex (PL-ASA) was designed to prevent this disruption. We sought to determine the pharmacokinetic (PK)/pharmacodynamic (PD) characteristics of PL-ASA compared with immediate release aspirin (IR-ASA). In this active-control crossover study, 32 healthy volunteers were randomized to receive 1 of 2 dose levels (a single dose of 325 mg or 650 mg) of either PL-ASA or IR-ASA. After a 2-week washout period between treatment assignments, subjects received a single dose of the alternative treatment, at the same dose level. The primary objectives of the study were to assess, for PL-ASA and IR-ASA at 325 mg and 650 mg dose levels, PK and PD bioequivalence, and safety, over a 24–h period after administration of both drugs. PK parameters were similar for PL-ASA and IR-ASA, and met FDA-criteria for bioequivalence. Regarding PD, both drugs also showed Cmin TxB2 values below 3.1 ng/mL (cut-off associated with decreased cardiovascular events) and > 99{\%} inhibition of serum TxB2 (≥ 95{\%} inhibition represents the cut-off for aspirin responders) along with similar results in several secondary PK/PD parameters. There were no serious adverse events or changes from baseline in vital signs or laboratory values in either of the 2 treatment groups. PL-ASA’s novel liquid formulation has similar PK and PD performance compared with IR-ASA, supporting functional and clinical equivalence. These data coupled with the improved gastric safety of PL-ASA suggest that this novel formulation may exhibit an improved benefit-risk profile, warranting evaluation in future trials. Clinical trial registration:http://www.clinicaltrials.gov. Unique Identifier: NCT04008979.",
keywords = "Aspirin, Bioequivalence, Pharmacodynamic, Pharmacokinetic, Platelet",
author = "Angiolillo, {Dominick J.} and Bhatt, {Deepak L.} and Frank Lanza and Byron Cryer and Dong, {Jin fei} and Walter Jeske and Zimmerman, {Ronald R.} and {von Chong}, Estela and Jayne Prats and Deliargyris, {Efthymios N.} and Upendra Marathi",
year = "2019",
month = "1",
day = "1",
doi = "10.1007/s11239-019-01933-7",
language = "English (US)",
journal = "Journal of Thrombosis and Thrombolysis",
issn = "0929-5305",
publisher = "Springer Netherlands",

}

TY - JOUR

T1 - Pharmacokinetic/pharmacodynamic assessment of a novel, pharmaceutical lipid–aspirin complex

T2 - results of a randomized, crossover, bioequivalence study

AU - Angiolillo, Dominick J.

AU - Bhatt, Deepak L.

AU - Lanza, Frank

AU - Cryer, Byron

AU - Dong, Jin fei

AU - Jeske, Walter

AU - Zimmerman, Ronald R.

AU - von Chong, Estela

AU - Prats, Jayne

AU - Deliargyris, Efthymios N.

AU - Marathi, Upendra

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Aspirin (acetylsalicylic acid, ASA) can lead to gastrointestinal mucosal injury through disruption of its protective phospholipid bilayer. A liquid formulation of a novel pharmaceutical lipid–aspirin complex (PL-ASA) was designed to prevent this disruption. We sought to determine the pharmacokinetic (PK)/pharmacodynamic (PD) characteristics of PL-ASA compared with immediate release aspirin (IR-ASA). In this active-control crossover study, 32 healthy volunteers were randomized to receive 1 of 2 dose levels (a single dose of 325 mg or 650 mg) of either PL-ASA or IR-ASA. After a 2-week washout period between treatment assignments, subjects received a single dose of the alternative treatment, at the same dose level. The primary objectives of the study were to assess, for PL-ASA and IR-ASA at 325 mg and 650 mg dose levels, PK and PD bioequivalence, and safety, over a 24–h period after administration of both drugs. PK parameters were similar for PL-ASA and IR-ASA, and met FDA-criteria for bioequivalence. Regarding PD, both drugs also showed Cmin TxB2 values below 3.1 ng/mL (cut-off associated with decreased cardiovascular events) and > 99% inhibition of serum TxB2 (≥ 95% inhibition represents the cut-off for aspirin responders) along with similar results in several secondary PK/PD parameters. There were no serious adverse events or changes from baseline in vital signs or laboratory values in either of the 2 treatment groups. PL-ASA’s novel liquid formulation has similar PK and PD performance compared with IR-ASA, supporting functional and clinical equivalence. These data coupled with the improved gastric safety of PL-ASA suggest that this novel formulation may exhibit an improved benefit-risk profile, warranting evaluation in future trials. Clinical trial registration:http://www.clinicaltrials.gov. Unique Identifier: NCT04008979.

AB - Aspirin (acetylsalicylic acid, ASA) can lead to gastrointestinal mucosal injury through disruption of its protective phospholipid bilayer. A liquid formulation of a novel pharmaceutical lipid–aspirin complex (PL-ASA) was designed to prevent this disruption. We sought to determine the pharmacokinetic (PK)/pharmacodynamic (PD) characteristics of PL-ASA compared with immediate release aspirin (IR-ASA). In this active-control crossover study, 32 healthy volunteers were randomized to receive 1 of 2 dose levels (a single dose of 325 mg or 650 mg) of either PL-ASA or IR-ASA. After a 2-week washout period between treatment assignments, subjects received a single dose of the alternative treatment, at the same dose level. The primary objectives of the study were to assess, for PL-ASA and IR-ASA at 325 mg and 650 mg dose levels, PK and PD bioequivalence, and safety, over a 24–h period after administration of both drugs. PK parameters were similar for PL-ASA and IR-ASA, and met FDA-criteria for bioequivalence. Regarding PD, both drugs also showed Cmin TxB2 values below 3.1 ng/mL (cut-off associated with decreased cardiovascular events) and > 99% inhibition of serum TxB2 (≥ 95% inhibition represents the cut-off for aspirin responders) along with similar results in several secondary PK/PD parameters. There were no serious adverse events or changes from baseline in vital signs or laboratory values in either of the 2 treatment groups. PL-ASA’s novel liquid formulation has similar PK and PD performance compared with IR-ASA, supporting functional and clinical equivalence. These data coupled with the improved gastric safety of PL-ASA suggest that this novel formulation may exhibit an improved benefit-risk profile, warranting evaluation in future trials. Clinical trial registration:http://www.clinicaltrials.gov. Unique Identifier: NCT04008979.

KW - Aspirin

KW - Bioequivalence

KW - Pharmacodynamic

KW - Pharmacokinetic

KW - Platelet

UR - http://www.scopus.com/inward/record.url?scp=85070946243&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070946243&partnerID=8YFLogxK

U2 - 10.1007/s11239-019-01933-7

DO - 10.1007/s11239-019-01933-7

M3 - Article

C2 - 31420787

AN - SCOPUS:85070946243

JO - Journal of Thrombosis and Thrombolysis

JF - Journal of Thrombosis and Thrombolysis

SN - 0929-5305

ER -